Takeover expands SSB’s service portfolio Glasgow, April 17, 2015 – BioOutsource Ltd. (BioOutsource), a leading provider of contract testing services for the biopharmaceutical industry, has been acquired by Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries. BioOutsource provides contract testing services to Global biopharmaceutical clients in order to monitor the safety More
Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more More
Chief Scientific Officer, Daniel Galbraith comments in Pharmaceutical Technology Magazine article, An Orthogonal Approach to Biosimilarity.
Chief Scientific Officer, Daniel Galbraith reviews the Biosimilars market and models for reducing costs in article for Drug Discovery News. Read the article here.
Free Webinar to Explore Comparability Challenges Faced by Developers of Biosimilars GLASGOW, Scotland and CAMBRIDGE, Mass. – 9 February 2015 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced that it will be hosting a free webinar on Thursday, 12 February, at 3:00 p.m. More
Already a Leader in Comparability of Biosimilars, New R&D Initiative Aligns BioOutsources’ Strategy with the Next Generation of Biosimilars, to Support Client Testing Requirements and Leverage Rapid Growth in Biosimilars Market GLASGOW, Scotland and CAMBRIDGE, Mass. – 3rd November 2014 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterisation for More
Adventitious agent testing using in vivo protocols: a BioOutsource Position Paper (2014).
The approaching biosimilars tidal wave puts the question of animal testing for biologics further under scrutiny. Read our Chief Scientific Officer, Dr Daniel Galbraith’s article in GEN Exclusives. Follow this link to read the full article. For more detail on this issue, read our team’s position paper: Adventitious agent testing using in vivo protocols: A BioOutsource Position More
CSO, Dr Daniel Galbraith’s article on how biosimilars have prompted CROs to be more flexible and for developers to seek focused, niche testing partners.
GLASGOW, Scotland. – 19 June, 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organisation (CTO) today announced their partnership with PsiOxus Therapeutics Ltd. to support clinical sample analysis of their Phase I/II OCTAVE (Ovarian Cancer) study. PsiOxus Therapeutics, Ltd., an Oxford, based biotechnology company, has been awarded a £1.7 million grant towards a Phase More